INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
81.31
+1.08 (+1.35%)
At close: 4:00PM EDT

81.31 0.00 (0.00%)
After hours: 4:07PM EDT

Stock chart is not supported by your current browser
Previous Close80.23
Open80.35
Bid75.03 x 800
Ask81.08 x 1000
Day's Range80.14 - 81.47
52 Week Range57.00 - 89.30
Volume616,940
Avg. Volume1,276,880
Market Cap17.436B
Beta (3Y Monthly)0.98
PE Ratio (TTM)69.97
EPS (TTM)1.16
Earnings DateJul 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.07
Trade prices are not sourced from all markets
  • Business Wire8 days ago

    Incyte to Report Second Quarter Financial Results

    Incyte Corporation announced today that it has scheduled its second quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2019.

  • Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
    Zacks9 days ago

    Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA

    FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications

  • GuruFocus.com10 days ago

    5 Immunotherapy Stocks to Keep a Close Eye On

    Immunotherapy is changing the face of cancer treatment as we know it, creating compelling investment opportunities

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.30 billion over the last one-month into ETFs that hold INCY are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MarketWatch11 days ago

    Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing

    Shares of health companies were down Monday, with both the Health Care Select Sector SPDR Fund ETF and the SPDR S&P Pharmaceuticals ETF falling 0.6% in morning intraday trade. Shares of Cardinal Health Inc. led the losers in the S&P 500's health-care ETF, falling 3.1% after the company said CFO Jorge Gomez would leaving the company, followed by declines in shares of Incyte Corp , Alexion Pharmaceuticals Inc. , and Biogen Inc. , Regeneron Pharmaceuticals Inc. and Amgen Inc. . The dip in health-care stocks comes after President Trump's announcement Friday that he was planning to soon issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries. "Our guess is drug stocks may be initially pressured this week," Jefferies health-care trading desk strategist Jared Holz wrote in an email to clients on Sunday evening. However, "feedback already suggests investors believe the executive order, if it comes to pass, will only be relevant for a handful of drugs (those that are very significant in revenue and administered in a physician's office)... at least at the onset," he wrote. The drop in health shares comes amid a broader decline in U.S. stocks, as investors grapple with doubts about whether the Federal Reserve will still cut interest rates after a strong U.S. jobs report Friday. The S&P 500 was down 0.4% Monday morning. The index has gained 18.8% in the year to date.

  • With A 12% Return On Equity, Is Incyte Corporation (NASDAQ:INCY) A Quality Stock?
    Simply Wall St.16 days ago

    With A 12% Return On Equity, Is Incyte Corporation (NASDAQ:INCY) A Quality Stock?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
    Zacks16 days ago

    Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab

    Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.

  • Incyte signs $77.5M collaboration and licensing deal with Chinese biopharmaceutical company
    American City Business Journals17 days ago

    Incyte signs $77.5M collaboration and licensing deal with Chinese biopharmaceutical company

    The deal, which involves an Incyte monoclonal antibody being developed as a cancer treatment, includes a $17.5 million upfront payment.

  • MarketWatch17 days ago

    Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China

    Incyte Corp. said Tuesday it will receive an upfront payment of $17.5 million as part of a license agreement with Zai Lab Ltd. for the development and commercialization of Incyte's cancer treatment INCMGA0012 in China. Under terms of the agreement, Incyte is eligible to receive up to an additional $60 million in milestone payments, as well as tiered royalty payments from the "low to mid-twenties." In return, Zai Lab will have exclusive rights to commercialize INCMGA0012 in China, Hong Kong, Macau and Taiwan. Incyte and Zai Lab shares were still inactive in the premarket. Over the past three months, Incyte shares have lost 1.5% and Zai Lab's stock has climbed 19.4%, while the iShares Nasdaq Biotechnology ETF has slipped 2.7% and the S&P 500 has gained 3.4%.

  • Business Wire17 days ago

    Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China

    Incyte (INCY) and Zai Lab Ltd. (ZLAB) today announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. Under the terms of the agreement, Zai Lab will pay Incyte US$17.5 million up front, and Incyte is eligible to receive up to an additional US$60 million in potential development, regulatory and commercial milestones, as well as tiered royalties from the low to mid-twenties, with Incyte responsible for all royalties and pass-through payments to its licensing partner, MacroGenics, Inc. Zai Lab will receive the rights to develop and exclusively commercialize INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.

  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch27 days ago

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
    Zacks29 days ago

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

  • Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
    Zackslast month

    Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

    A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

  • Merck's Keytruda Gets 2nd Label Expansion Approval in June
    Zackslast month

    Merck's Keytruda Gets 2nd Label Expansion Approval in June

    Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.

  • TheStreet.comlast month

    2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

    "Merger Monday" finally lived up to its billing this week in Biotech Land. announced just before the opening bell Monday that it was acquiring oncology concern Array Biopharma Inc. Pfizer paid a buyout premium of more than 60% to purchase Array.

  • Cancer Therapy Stocks Soar After Pfizer Deal
    Investopedialast month

    Cancer Therapy Stocks Soar After Pfizer Deal

    Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.

  • Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
    MarketWatchlast month

    Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

    Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.

  • Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up
    Investor's Business Dailylast month

    Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up

    Bitcoin trading was active again Monday amid a solid gain for the Nasdaq. The tech-laden index was helped by strength in software and biotech stocks.

  • 2 Rallying Pharma Stocks Roping In Option Bulls
    Schaeffer's Investment Researchlast month

    2 Rallying Pharma Stocks Roping In Option Bulls

    Short sellers could be shaking in their boots

  • Business Wirelast month

    Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

    Incyte (INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75 years of age) with vitiligo. The study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved a ≥50 percent improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with a vehicle control (non-medicated cream).

  • Here’s What Hedge Funds Think About Incyte Corporation (INCY)
    Insider Monkeylast month

    Here’s What Hedge Funds Think About Incyte Corporation (INCY)

    Is Incyte Corporation (NASDAQ:INCY) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]

  • Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
    Zackslast month

    Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I

    Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.